Evinacumab is another monoclonal antibody that pharmacologically inhibits angiopoietin-like 3 (ANGPTL3) and was recently approved by the FDA as a complementary agent to other LDL-C-lowering therapies for patients with homozygous familial hypercholesterolemia (HoFH). This evidence concerns the gene ANGPTL3 and homozygous familial hypercholesterolemia.